Salvianolic acid A (Synonyms: Dan Phenolic Acid A, (+)-Salvianolic Acid A) |
| Catalog No.GN10211 |
Salvianolic acid A is a polyphenolic compound with multi-target pharmacological activities. Salvianolic acid A inhibits the activity of the TGF-β1 signaling pathway by targeting TGF-β receptor I (TβRI) and downregulates the expression of MMP9 protein. Salvianolic acid A is commonly used in cardiovascular diseases and organ fibrosis research.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 96574-01-5
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Salvianolic acid A is a polyphenolic compound with multi-target pharmacological activities. Salvianolic acid A inhibits the activity of the TGF-β1 signaling pathway by targeting TGF-β receptor I (TβRI) and downregulates the expression of MMP9 protein[1]. Salvianolic acid A is commonly used in cardiovascular diseases and organ fibrosis research. Derived from Salvia miltiorrhiza (Danshen), Salvianolic acid A suppresses mitochondrial lipid peroxidation, maintains ATPase activity, eliminates superoxide, and exhibits strong antioxidant and neuroprotective effects[2]. Additionally, Salvianolic acid A demonstrates broad pharmacological activities, including anti-inflammatory, anticancer, and antifibrotic properties[3, 4].
In vitro, in a hemorrhagic stroke model using hemin-incubated cortical neuronal cells, Salvianolic acid A (30-60μM) improved cell viability, enhanced the expression of Solute Carrier Family 7 Member 11 (XCT) and glutathione peroxidase 4 (GPX4), and reduced reactive oxygen species (ROS) production[5]. In hydrogen peroxide (H₂O₂)-induced human umbilical vein endothelial cell (HUVEC) injury models, Salvianolic acid A (0.25-16μM) treatment significantly increased cell viability and proliferation, reduced H₂O₂-induced cell death and oxidative stress, downregulated cell cycle-related proteins p53 and p21, and upregulated cyclin E1 levels[6].
In vivo, In chloroform-induced liver fibrosis rats treated with Salvianolic acid A (5, 15 mg/kg/day) via intraperitoneal injection for 6 weeks, Salvianolic acid A alleviated hepatic inflammation and fibrosis, reduced collagen deposition and pseudolobule formation, and decreased serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), hyaluronic acid (HA), laminin (LN), type IV collagen (CIV), and N-terminal propeptide of type III procollagen (PIIINP)[7]. In gentamicin-induced acute kidney injury rats treated with Salvianolic acid A (10, 20, 40mg/kg/day) via intraperitoneal injection for 7 days, Salvianolic acid A reduced renal index, serum levels of kidney injury molecule-1 (KIM-1), and neutrophil gelatinase-associated lipocalin (NGAL), as well as urinary protein levels[8].
References:
[1] QIN T, RASUL A, SARFRAZ A, et al. Salvianolic acid A & B: potential cytotoxic polyphenols in battle against cancer via targeting multiple signaling pathways [J]. Int J Biol Sci, 2019, 15(10): 2256-2264.
[2] QIU J M, QIN C F, WU S G, et al. A novel salvianolic acid A analog with resveratrol structure and its antioxidant activities in vitro and in vivo [J]. Drug Dev Res, 2021, 82(1): 108-114.
[3] ZENG X, CHEN X, QIN H, et al. Preventive effects of a natural anti-inflammatory agent Salvianolic acid A on acute kidney injury in mice [J]. Food Chem Toxicol, 2020, 135(110901.
[4] GONG D F, SUN S C, WANG R R, et al. Salvianolic acid A improve mitochondrial respiration and cardiac function via inhibiting apoptosis pathway through CRYAB in diabetic cardiomyopathy [J]. Biomed Pharmacother, 2023, 160(114382.
[5] SHI Y, YAN D, NAN C, et al. Salvianolic acid A inhibits ferroptosis and protects against intracerebral hemorrhage [J]. Sci Rep, 2024, 14(1): 12427.
[6] QIAO X, CAO S, CHEN S, et al. Salvianolic acid A alleviates H(2)O(2)-induced endothelial oxidative injury via miR-204-5p [J]. Sci Rep, 2024, 14(1): 11931.
[7] WANG R, SONG F, LI S, et al. Salvianolic acid A attenuates CCl(4)-induced liver fibrosis by regulating the PI3K/AKT/mTOR, Bcl-2/Bax and caspase-3/cleaved caspase-3 signaling pathways [J]. Drug Des Devel Ther, 2019, 13:1889-1900.
[8] DIAO H Y, ZHU W, LIU J, et al. Salvianolic Acid A Improves Rat Kidney Injury by Regulating MAPKs and TGF-beta1/Smads Signaling Pathways [J]. Molecules, 2023, 28(8).
| Cell experiment [1]: | |
Cell lines | HUVEC cells |
Preparation Method | HUVEC cells were seeded in 96-well plates (1 × 104 cells/mL, 100 μL/well), Cells were exposed to 200μM H2O2 for 12 h in serum-free medium following 24 h of normal culture. After H2O2 inducing, cells were treated with different concentrations of Salvianolic acid A (0, 0.25, 0.5, 1, 2, 4, 8, 16μM) for 24h. CCK-8 was added into each well and incubated at 37 °C for 2h. The absorbance was measured at 450nm. |
Reaction Conditions | 0, 0.25, 0.5, 1, 2, 4, 8, 16μM; 24h |
Applications | Salvianolic acid A improved the cell viability of H2O2 inducing HUVEC cells. |
| Animal experiment [2]: | |
Animal models | Sprague-Dawley rats |
Preparation Method | Male Sprague-Dawley rats were received CCl4 orally to induce liver fibrosis. Thereafter, the rats were intraperitoneally administered Salvianolic acid A (5 or 15mg/kg) once daily for 6 successive weeks. Blood samples were obtained from the abdominal aorta. The tissue samples of liver were fixed in 10% neutral formalin. Remaining tissues from the liver were stored at −80°C for future use. |
Dosage form | 5 and 10mg/kg/day for 6 weeks; i.p. |
Applications | Salvianolic acid A alleviated liver injury, fibrosis, hepatocyte apoptosis, and serum level of hydroxyproline. |
References: | |
| Cas No. | 96574-01-5 | SDF | |
| Synonyms | Dan Phenolic Acid A, (+)-Salvianolic Acid A | ||
| Chemical Name | (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-[2-[(E)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid | ||
| Canonical SMILES | C1=CC(=C(C=C1CC(C(=O)O)OC(=O)C=CC2=C(C(=C(C=C2)O)O)C=CC3=CC(=C(C=C3)O)O)O)O | ||
| Formula | C26H22O10 | M.Wt | 494.45 |
| Solubility | ≥ 24.7mg/mL in Water with gentle warming | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0224 mL | 10.1122 mL | 20.2245 mL |
| 5 mM | 0.4045 mL | 2.0224 mL | 4.0449 mL |
| 10 mM | 0.2022 mL | 1.0112 mL | 2.0224 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *